Movement Alert｜Natera Intraday Rise 3.15% in Regular Trading, Price Target Hike and Cancer Testing Progress Support Shares

Market Focus10-16

On October 16, Natera rose 3.15% in Regular Trading, trading at $406.9 per share, with turnover of $321 million.

The move coincided with a recent price target increase to $435 from $355 while the bank maintained an overweight rating, alongside continued attention on the company’s oncology testing pipeline.

Additional backdrop includes the FDA granting Breakthrough Device Designation to Natera’s multi-cancer early detection assay, Signatera receiving approval in Japan as a companion diagnostic for muscle-invasive bladder cancer, and ongoing clinical work in skin cancer and breast cancer. The company last reported second-quarter revenue of $752.8 million, up 37.7% year over year, and raised full-year revenue guidance to $2.85 billion to $2.91 billion, reinforcing the longer-term growth narrative.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment